Print Issue: July 01, 2010

Higher Hemoglobin Goals Raise Stroke Risk

A meta-analysis of 27 trials evaluating erythropoiesis-stimulating agent (ESA) treatment in 10,452 CKD patients shows that compared with a lower hemoglobin (Hb) target, higher Hb targets are associated with a 51% increased of stroke, a 67% increased risk of hypertension, and a 33% increased risk of vascular access thrombosis.

BP Lowering Better with a Triple Regimen

NEW YORK—An investigational triple regimen of olmesartan medoxomil (OM), amlodipine besylate (AML), and hydrochlorothiazide (HCTZ) may result in significantly greater mean reductions in BP compared with a combination of any two of these drugs in patients with moderate to severe hypertension, new data show.

Next post in Hypertension